Yarrow Bioscience (NASDAQ:YARW) Sees Significant Increase in Short Interest

Yarrow Bioscience (NASDAQ:YARW) saw a large increase in short interest during the month of September. As of September 15th, there was short interest totaling 126,528 shares, an increase of 123.9% from the August 31st total of 56,499 shares. Approximately 4.9% of the shares of the stock are sold short. Based on an average trading volume of 170,937 shares, the short-interest ratio is presently 0.7 days.

Yarrow Bioscience Stock Down 2.0%

Shares of NASDAQ:YARW opened at $25.54 on Friday. Yarrow Bioscience has a 52 week low of $16.00 and a 52 week high of $46.95. The stock has a market cap of $68.19 million, a PE ratio of -1.74 and a beta of 2.01. The business has a fifty day simple moving average of $34.10.

Yarrow Bioscience (NASDAQ:YARW) last announced its earnings results on Thursday, August 13th. The company reported ($3.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($3.33). Yarrow Bioscience had a negative net margin of 4,726.21% and a negative return on equity of 84.40%. The business had revenue of $0.10 million for the quarter, compared to analysts’ expectations of $0.20 million.

Yarrow Bioscience Announces Dividend

The business also recently disclosed a special dividend, which was paid on Thursday, July 23rd. Shareholders of record on Wednesday, July 22nd were given a dividend of $19.00 per share.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Wall Street Zen raised Yarrow Bioscience to a “hold” rating in a research note on Saturday, August 22nd. TD Cowen initiated coverage on Yarrow Bioscience in a research note on Tuesday, July 28th. They issued a “buy” rating on the stock. Finally, BTIG Research began coverage on Yarrow Bioscience in a report on Monday, August 3rd. They set a “buy” rating and a $58.00 price objective on the stock. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $58.00.

Hedge Funds Weigh In On Yarrow Bioscience

Institutional investors and hedge funds have recently modified their holdings of the stock. Nantahala Capital Management LLC bought a new position in shares of Yarrow Bioscience during the 2nd quarter valued at approximately $1,301,400,000. ADAR1 Capital Management LLC bought a new stake in Yarrow Bioscience in the second quarter worth $1,920,000. Braidwell LP purchased a new position in Yarrow Bioscience during the second quarter worth $596,000. T3 Companies LLC purchased a new position in Yarrow Bioscience during the fourth quarter worth $548,000. Finally, Susquehanna International Group LLP purchased a new position in Yarrow Bioscience during the second quarter worth $77,000. Hedge funds and other institutional investors own 83.78% of the company’s stock.

About Yarrow Bioscience

VYNE Therapeutics Inc, a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.